INVO Fertility, Inc (NASDAQ:IVF) Sees Significant Drop in Short Interest

INVO Fertility, Inc (NASDAQ:IVF) saw a significant decline in short interest in July. As of July 15th, there was short interest totaling 260,114 shares, a decline of 65.8% from the June 30th total of 760,242 shares. Currently, 14.6% of the shares of the stock are sold short. Based on an average daily volume of 358,678 shares, the days-to-cover ratio is currently 0.7 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in INVO Fertility stock. Citadel Advisors LLC acquired a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to its most recent filing with the SEC. The firm acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, INVO Fertility has a consensus rating of “Moderate Buy” and an average price target of $20.00.

INVO Fertility Trading Up 2.2%

Shares of NASDAQ IVF opened at $0.98 on Wednesday. INVO Fertility has a 1-year low of $0.91 and a 1-year high of $90.80. The company has a market cap of $2.25 million, a PE ratio of -0.00 and a beta of 2.28. The company has a current ratio of 0.90, a quick ratio of 0.87 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $1.43 and a two-hundred day moving average of $3.05.

INVO Fertility (NASDAQ:IVF) last announced its earnings results on Monday, June 22nd. The company reported ($3.38) earnings per share (EPS) for the quarter. INVO Fertility had a negative return on equity of 420.62% and a negative net margin of 183.75%.The company had revenue of $2.02 million for the quarter.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.